NFE2L2 and hepatocellular carcinoma: Since the status of NRF2 is a key factor determining the therapeutic response to ferroptosis-targeted therapies in HCC cells (Sun et al., 2016), inhibiting the expression of NRF2 during ferroptosis-targeted therapies to enhance curative tumor effects is necessary.